Introduction
Ovarian cancer is the fourth leading cause of cancer related deaths in women following breast, lung and colon cancer. Epithelial ovarian cancer (EOC) is the most common form of human ovarian cancer (reviewed in Auersperg et al., 2001) . One approach to understanding the genetic and epigenetic events that contribute to EOC is to identify genes that are dierentially expressed during neoplastic progression. The rationale in this strategy is that these dierentially expressed genes may themselves be directly involved in transformation, or alternatively the promoter of these genes respond to transcription factors whose modulation is important during tumorigenesis. This approach has been recently revolutionized by the development of high throughput methodologies that permit the quanti®cation of expression of large sets of transcripts simultaneously. Using technologies such as microarray analysis it has been possible to identify signature patterns of expression in tumor samples that correlate with the biology of the system under study (Alizadeh et al., 2000; Bittner et al., 2000; Golub et al., 1999; Perou et al., 2000; Ross et al., 2000; St Croix et al., 2000; Staudt, 2000) . Several groups have already applied this technology to the ovarian cancer problem (Ono et al., 2000; Wang et al., 1999; Welsh et al., 2001) .
Cancer cell lines have remained an important resource for understanding the underlying molecular events that accompany oncogenesis. The study of cancer cell lines carry a number of advantages including the purity of the research material, the ability to generate sucient quantities of DNA, RNA and protein extracts for numerous studies as well as the ability to genetically manipulate cell lines allowing a wide range of in vitro and in vivo xenograft studies. Ideally, clinical pro®les accompanied by a detailed molecular characterization would make cell lines a more attractive model. We previously described a method for the establishment of primary cultures derived from benign tumors, malignant tumors and ascites of the ovary that are representative of the original clinical material from which they are derived (Lounis et al., 1994) . Using this approach we derived a number of spontaneously immortalized cell lines. Four long-term cell lines were derived from ovarian malignant tumors (TOV-21G, TOV-81D and TOV-112D) and from an ovarian malignant ascites (OV-90) from chemotherapy naõÈ ve patients. These cell lines were characterized by morphological, immunohistochemical, cytogenetic and molecular analysis (Provencher et al., 2000) . They harbor mutations in genes that have been implicated in ovarian cancer such as TP53, CDNK2A, TGF-b-RII and BRCA2. Notably, these cell lines display growth characteristics in vitro that mimic their clinical behavior. Here we report the pattern of gene expression identi®ed by microarray analysis for TOV-21G, TOV-81D, OV-90 and TOV-112D. For comparative purposes, we also report the expression pro®le for a primary culture from normal surface ovarian epithelium (NOV-31) and for RNA from a solid ovarian tumor tissue (TOV-578G).
Results

Data validation
Expression pro®les were generated using the Hs6000 gene chip with total RNA from NOV-31, TOV-21G, TOV-81D, OV-90, TOV-112D and TOV-578G (Table  1) . Two strategies were pursued to validate these data sets. The ®rst strategy was based upon a comparison of expression pro®les of dierent probe sets that were mapped to the same UniGene cluster (Figure 1a) . The Hs6000 microarray contained dierent representations of osteonectin (SPARC) and apolipoprotein E (APOE). As illustrated by these examples ( Figure  1a ), while there may be dierences in the absolute numerical value assigned to the gene expression (maximum variance observed is 2 ± 3-fold), the expression pro®les of the six samples are comparable for each representation of the same gene. Exceptions to pattern conservation were seen in genes like the deathassociated protein kinase 1 (DAPK1) where the numerical values of expression are below 100 ( Figure  1a) . It has been shown that the reproducibility of expression quantitation is more variable at these values (J Novak, personal communication). In addition, we have results showing that by comparing multiple arrays from the same cell line (using the HuGeneFL array) the biological and technical variation is less than threefold for 99.5% of genes having signal intensities greater than 100 (J Novak and T Hudson, in preparation). The second strategy was based on a comparison of expression pro®les with Northern blot analysis. Figure 1b provides examples of Northern blots and numerical microarray data for corresponding probe sets. GAPDH expression was used as an internal control in Northern analysis and varied by less than twofold by microarray analysis. Expression pro®les for genes showing greater than threefold dierences generally displayed good concordance between the microarray data and Northern analysis (see for example MYC and HSPD1). When less than threefold variations between samples was observed, patterns tended to be similar but not identical (see for example KIAA0064 and PGAM1). In these experiments, data interpretation was more questionable at microarray levels of less than 100, as patterns and fold-comparisons were more variable (see for example TP53).
Two-and six-way sample comparisons
Large scale data analysis was performed with a dataset containing values of at least one P (i.e. present) call and an expression value of 4100. In addition, in order not to overestimate the dierences between expression pro®les, the expression data less than 100 were reassigned a value of 100. Using these stringent criteria, 1815 probe sets (from an original 6416) were selected for analysis. A minimum of a threefold dierence in expression values using the modi®ed dataset was deemed signi®cant.
We calculated the number of three-, ®ve-and 10-fold dierences in all possible two-way comparisons between samples. Individual two-way comparisons of NOV-31 to each individual ovarian tumor sample indicate that TOV-81D most closely resembles NOV-31 (Figure 2a) . These results are consistent with our previous study of the EOC cell lines that showed that TOV-81D, derived from a patient with indolent disease, displayed characteristics consistent with the least aggressive form of the disease (Provencher et al., . As a group, samples derived from tumors associated with aggressive disease (TOV-21G, OV-90, TOV-112D and TOV-578G) are signi®cantly more dierent from NOV-31 than TOV-81D (Figure 2a ).
Two-way comparisons of each sample to TOV-112D indicate the strongest similarity, although subtle, of over expression pro®les between that of TOV-112D and TOV-578G ( Figure 2b ). This observation may re¯ect the similar endometrioid histology of these two samples, and occurs despite the fact that TOV-578G is derived from a tumor biopsy that is likely contaminated with dierent cell types. This cell contamination was clearly exempli®ed by the signi®cant expression of hemoglobin in TOV-578G (with values 4500 for both g-and b-hemoglobin) as compared with little or no signal (values 560) in all samples representing the EOC cell lines. Simultaneous six-way comparisons of each sample to NOV-31 revealed patterns of expression distinguishing normal from tumor derived material. The number of times the expression level exceeded that of NOV-31 for a given probe set is indicated in Figure 2c . In this analysis, it is apparent that the majority of probe sets varied in expression only in one sample (n=280, threefold) while that of individual probe sets varied less frequently over two (n=85, threefold), three (n=48, threefold), four (n=23, threefold) and all ®ve tumor samples (n=1, threefold). In contrast, those that were under-expressed as compared to NOV-31 showed a dierent pattern of down-regulation (Figure 2d ), in that a large number of probe sets varied simultaneously in at least three tumor samples. While relatively few probe sets showed down-regulation in all ®ve samples (n=9, threefold) several varied in four (n=32, threefold), three (n=24, threefold), two (n=20, threefold) and one (n=32, threefold) tumor sample. Many of the probe sets that varied in four samples did not vary in TOV-81D as compared to NOV-31 (23 of 32, at threefold), again pointing to similarities between the expression pro®les of NOV-31 and TOV-81D. In addition, it was noted that probe sets were more frequently over-expressed (n=437, threefold) than under-expressed (n=117, threefold) in the tumor samples when compared to NOV-31 levels of expression.
Comparison of expression profiles with respect to chromosome location of probe sets
We compared the expression levels in the NOV-31 and the EOC samples where chromosomal assignment of genes or ESTs represented by probe sets is known. The chromosome mapping information was retrieved for the 1815 GenBank assession numbers representative of the probe sets on the Aymetrix GeneChip. Of these, 1226 were assigned to unique chromosomes based on Gene Map 98 as described in UniGene-Homo sapiens (Table 2) . Only unambiguously mapped genes/ESTs where one chromosome location was reported are indicated. The uneven distribution per chromosome is a re¯ection of the dierences in the number of expressed sequences (genes) on speci®c chromosomes which implies that some chromosomes are gene rich such as chromosome 19 (Hudson et al., 1995; Saccone et al., 1992) . For the genes/ESTs with unique Comparative analysis of expression pro®les between microarray and Northern blot analysis. Northern blots were normalized to a GAPDH probe hybridized on the same membrane. Numerical data from the microarray readings were plotted. Black and grey columns in the TP53 and PGAM1 microarray data panels represent probe sets derived from dierent genes/ESTs chromosome map locations, comparisons were made between the expression levels in the NOV-31 and each EOC cell sample ( Table 2 ). The expression pro®les for the vast majority (480%) did not dier greater than threefold in comparison to the NOV-31. Those that displayed greater than threefold dierences in expression levels were grouped according to those displaying increased or decreased levels of expression in comparison to NOV-31. The patterns of expression exhibited by the chromosome mapped genes/ESTs are consistent with overall expression pattern observed by the alternative analysis of the probe sets as described above. Among the expression pro®les of tumor derived cell lines, the tumor cell line with the least aggressive phenotype, TOV-81D, displayed the fewest dierences over all chromosomes in comparison to that of NOV-31 (Table 2) . We have investigated if the similarity in expression pro®les between NOV-31 and TOV-81D extends to the probe sets that map to individual chromosomes. Figure 3 features an analysis of the expression pro®le of those that map to chromosome 6. This chromosome is featured because it has been implicated in ovarian tumorigenesis. There were 61 genes/ESTs that mapped to chromosome 6. Three were removed from this analysis because the accession numbers were no longer listed in UniGene database (in two cases) or because of ambiguous mapping information (in one case) as of March, 2000. The Greater than threefold dierence in the expression pro®les was variable with samples representative of the most aggressive tumorigenic phenotype. However, the probe sets representing R46753 and X78947 displayed a similar dierential pattern of expression in comparison to NOV-31 and TOV-81D. These sequences represent connective tissue growth factor (CTGF) and cyclin-dependent kinase inhibitor 1A (CDKN1A). The probe set representing D13315 also displayed an interesting expression pattern based on the increased expression in ovarian tumor samples derived from solid tumors (TOV-21G, TOV-112D and TOV-578) versus the expression pro®le in the tumor sample derived from an ovarian ascites, OV-90. The patterns displayed by these genes would suggest a role in tumors of advanced grade/stage or a role related to the pathology of ascites formation and thus warrant further investigation in a larger series of samples.
Discussion
In the study of complex diseases such as cancer, the development of good model systems is of primordial importance. Most human ovarian cancer cell lines described were derived from ascites or pleural eusion (Alama et al., 1996; Bast et al., 1981; Buller et al., 1995; DiSaia et al., 1975; Fogh and Trempe, 1975; Golombick and Bezwoda, 1991; Golombick et al., 1990; Grunt et al., 1993; Hamilton et al., 1983; Hirte et al., 1994; Langdon et al., 1988; Provencher et al., 1993; Sinna et al., 1979; Wong et al., 1990; Yamada et al., 1991) , with only a few cell lines derived from primary ovarian solid tumors (Crickard et al., 1989; Langdon et al., 1988; Woods et al., 1979) or metastases (Buick et al., 1985) . In addition, most cell lines originate from tumor material obtained following adjuvant therapy such as chemotherapy or radiation therapy, which could introduce confounding genetic events. In several cases little attention has been paid to the molecular characterization of these cell lines, and in particular it is often impossible to relate a given molecular event to the primary tumor from which it was derived. In many cases clinical pro®les are lacking thereby preventing comparisons between the initial tumor and the cell lines derived thereof. Thus additional well characterized cell lines provide new cellular tools to address the molecular and cellular events important in the development of EOC and TOV-TOV-OV-TOV-TOV-TOV-TOV-OV-TOV-TOV-TOV-TOV-OV-TOV-TOVno.  ESTs* 81D  21G  90  112D  578G  81D  21G  90  112D 578G  81D  21G  90  112D 578G   1  129  125  110  105  113  110  2  13  18  11  12  2  6  6  5  7  2 Here we describe microarray expression analysis for four new recently described ovarian cancer cell lines (Provencher et al., 2000) . The data analysis was performed on a fold-dierence basis, since this type of analysis is most appropriate when comparing a small number of cell lines isolated from histologically distinct tumors and from patients with dierent clinical pro®les. Our results demonstrate a concordance between biological parameters and microarray expression results. Expression analysis reveals the highest similarity between a primary culture derived from the normal ovarian surface epithelium (NOV-31) and a cell line (TOV-81D) derived from a patient with indolent disease (49 years survival despite stage 3C, grade 2 disease at initial surgery). We have extended our analysis to 12 NOV primary cultures (including NOV-31) as well as all cell lines with the HuGeneFL array (Mes-Masson, Tonin and Hudson, unpublished results). Using this data for two-way comparisons we conclude that all NOVs are more similar to each other than to any cell line and TOV-81D is again more similar to any given NOV. In addition, dierent cell lines were less similar to each other than two RNA samples derived from material of the same endometrioid histopathology (TOV-112D and TOV-578G) despite the fact that a cell line was compared to a fresh biopsied tumor sample. The concordance in the TOV-112D and TOV-578G expression patterns also suggest that cell lines re¯ect some of the underlying biological alterations seen in the primary tumor.
It is possible to compare the expression pattern of genes previously described in ovarian cancer (Anttila et al., 1999; Asschert et al., 1997; Barboule et al., 1998; Brown et al., 1999; Chambers et al., 1998; Courjal et al., 1996; Huleihel et al., 1997; Mok et al., 1996; Neyns et al., 1996; Tanner et al., 1998; Wysocki et al., 1990) with the expression values generated by microarray analysis. Some of the examples in Table 3 illustrate the concordance in microarray analysis with previous published reports based on Northern blot analysis and immunohistochemistry. In particular, both CDKN1A (Anttila et al., 1999) and SPARC (Mok et al., 1996) have been shown to be down-regulated in aggressive ovarian cancer and this mirrors the situation revealed by microarray expression analysis in our model. Once again, for these genes the pattern of expression of NOV-31 and TOV-81D are highly similar, and contrast sharply with the aggressive EOC samples. OV-90 has been classi®ed an ovarian adenocarcinoma as it maintains insucient dierentiated features Figure 3 Expression pro®le of ESTs or genes representative of probe sets assigned to chromosome 6 for the ®ve EOC cell lines and tumor tissue samples. The dierent ESTs/or genes were mapped according to cytogenetic position and genetic map coordinates to allow a more precise classi®cation by cell type. Over-expression of TFF1 has previously been correlated with the mucinous subtype of EOC (Wysocki et al., 1990) , and it will be interesting to determine if the expression patterns of genes like TFF1 will allow us to eventually better classify ovarian adenocarcinomas.
Chromosomal abnormalities such as chromosome gains and losses are a common feature of ovarian cancer cells. In anticipation of identifying patterns of gene expression that can be related to chromosome gains or losses that occur frequently in ovarian cancer (Mitelman et al., 1997) , we analysed the expression values of genes or ESTs that have been chromosome mapped. There were no obvious expression patterns associated with particular chromosomes. However, this may be a re¯ection of the lack of sucient coverage per chromosome and this limitation will become less important with the development of higher density microarrays covering a greater portion of the genome. Nonetheless, despite the low coverage, our analysis reinforces the notion that even at the chromosome level, similarities between NOV-31 and TOV-81D are the most striking.
Several groups have previously published microarray data comparing dierent ovarian tumors and ovarian cell lines. Although not always possible, at least some comparisons between their data and those for the four new cell lines are possible. In particular, overexpression of CD24, HE4, CD9 and MUC1 was correlated with ovarian carcinogenesis (Welsh et al., 2001) and we note a similar overexpression in some of the aggressive lines although these genes are never overexpressed in TOV-81D. Similar overexpression of HE4 were separately identi®ed by others (Ono et al., 2000; Wang et al., 1999) . The overexpression of several keratins in ovarian tumors has also been noted by microarray analysis (Welsh et al., 2001) . We observed a similar overexpression of keratins 8, 9, 10, 18 and 19 in the TOV-21G, OV-90, TOV-112D and TOV-578G samples. In contrast, only keratin 18 appears to be overexpressed in TOV-81D. Finally both MACMARCKS (macrophage myristoylated alanine-rich C kinase substrate) and adenylosuccinate synthase were identi®ed as being up-regulated in ovarian tumors (Ono et al., 2000) . We observe a similar but not uniform up-regulation of these two genes although once again no such up-regulation is noted for TOV-81D. Therefore, limited comparison of expression data from the four cell lines with available published results con®rms the notion that NOV-31 and TOV-81D are more closely related than the tumorigenic cell lines TOV-21G, OV-90 and TOV-112D. Thus, comparison of our model and method of analysis demonstrates the similarity of expression of a small number of genes that have already been pro®led by others as to altered expression in ovarian cancer, and adds some measure of con®dence in the data presented herein. However, due in large part to the heterogeneity of EOC, we and others need to extend our analysis to a larger number of cell lines, primary cultures and tumors, before we can identify signature expression pro®les and biologically important candidates which contribute to the biology of ovarian cancer.
The advent of new high-throughput technologies combined with the sequencing of the human genome has revolutionized our approach to studying complex diseases such as cancer. Results presented here and made available to ovarian cancer researchers (http:// genome.mcgill.ca/ovarian) provide an important framework for analysing both ovarian cancer and the in vitro model systems used to study this deadly disease.
Materials and methods
Cell culture and clinical material
A primary cell culture from a normal ovarian surface epithelium (NOV-31) was established as described (Kruk et al., 1990; Lounis et al., 1994) . EOC cell lines were maintained in OSE media consisting of 50 : 50 medium 199 : 105 (Sigma) (Kruk et al., 1990) supplemented with 10% fetal bovine serum (FBS) and 2.5 mg/ml fungizone and 50 mg/ml gentamicin. Biopsy material from an ovarian tumor (TOV-578G) was collected following surgery performed at the Centre Hospitalier de I'UniversiteÂ de MontreÂ al (HoÃ pital NotreDame) following appropriate consent. Disease was assigned a grade and stage according to the International Federation of Gynecology and Obstetrics (FIGO) criteria.
RNA extraction
Total RNA was extracted with TRIsol TM reagent (Gibco/ BRL, Life Technologies Inc., Grand Island, NY, USA). RNA was either extracted directly from a tumor biopsy (TOV-578G) or from cells grown to 80% con¯uency in 100 mm petri dishes.
Northern blots
Twenty mg of total RNA were electrophoresed on 1% (w/ v) agarose gel containing 2.2 M formaldehyde and 20 mM propane sulfonic acid, pH 6.8). RNA was transferred to nylon membranes (GeneScreen Plus TM , NEN products) by capillary blotting in 106SSC (16SSC is 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0). RNA was UV cross-linked and hybridized overnight at 608C in 30% formamide, 0.35 M sodium phosphate, pH 7.2, 7% SDS, 1% bovine serum albumin and an aliquot of the 32 P-dCTP-labeled probe. Membranes were subsequently washed twice at 608C with 0.15 M sodium phosphate, containing 1% SDS, and exposed to Kodak XAR-5 ®lm for 2 ± 5 days, at 7708C, with an intensifying screen. Membranes were treated at 808C for 1 h in 0.03 M sodium phosphate and 0.1% SDS, and exposed at 7708C with an intensifying screen overnight to insure that the probe had been removed prior to rehybridization. Probes were prepared from agarose gel puri®ed DNA fragments using a random primed labeling kit (Pharmacia) and subsequently puri®ed by the Nucleotide Removal kit (Qiagen). Probes were cloned and sequenced veri®ed prior to use.
Microarray analysis
Biotinylated hybridization target was prepared from total RNA as described . A complete protocol is available at http://www.genome.wi.mit.edu/ MPR. In summary, 20 mg of total RNA was reversetranscribed to double-stranded cDNA using oligo-dT primer containing T7 RNA polymerase binding site. This cDNA was then in vitro transcribed to cRNA using biotinylated dUTP and dCTP. The resulting cRNA`target' represents a labeled 50 ± 100-fold linear ampli®cation of the cDNA sample. To reduce secondary structure, the target was fragmented in 40 mM Tris acetate, 100 mM potassium acetate and 30 mM MgCl (pH 8.1) at 958C.
Hybridizations were performed with 15 mg of target on Aymetrix Hs6000 oligonucleotide microarrays containing probe sets for 6416 human genes (5223 known genes and 1193 ESTs). Following washing and staining, microarrays were scanned using a Hewlett Packard GeneArray scanner. Gene expression levels are calculated from the scanned image by Aymetrix GeneChip software giving a single average dierence ratio across 20 probe pairs as well as a reliability score (Ambiguous (A), Present (P), or Marginal (M) based on the variability of hybridization with each probe set).
Retrieval of information for probe sets
Information for each probe set was obtained from the UniGene-Homo sapiens designation (Unigene-Homo sapiens, 1999. National Center for Biotechnology Information http:www.ncbi.nlm.gov/UniGene) using a query that was designed to retrieve the corresponding UniGene name (cluster) for each GenBank asscession number that corresponded to the genes and ESTs represented on the GeneChip Hs6000. Then, additional information was retrieved for each cluster consisting of the gene symbol, the description of each gene, and the location on Gene Map 98. Retrieval from UniGene was performed in November, 1999. Additional information for selected genes was retrieved from GeneCards encyclopedia (Rebhan et al., 1997) .
